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Abstract
Background: Statistical models that use an individual’s DNA methylation levels to esti-
mate their age (known as epigenetic clocks) have recently been developed, with 96% cor-
relation found between epigenetic and chronological age. We postulate that differences
between estimated and actual age [age acceleration (AA)] can be used as a measure of
developmental age in early life.
Methods: We obtained DNA methylation measures at three time points (birth, age 7
years and age 17 years) in 1018 children from the Avon Longitudinal Study of Parents
and Children (ALSPAC). Using an online calculator, we estimated epigenetic age, and
thus AA, for each child at each time point. We then investigated whether AA was pro-
spectively associated with repeated measures of height, weight, body mass index (BMI),
bone mineral density, bone mass, fat mass, lean mass and Tanner stage.
Results: Positive AA at birth was associated with higher average fat mass [1321 g per
year of AA, 95% confidence interval (CI) 386, 2256 g] from birth to adolescence (i.e. from
age 0–17 years) and AA at age 7 was associated with higher average height (0.23 cm per
year of AA, 95% CI 0.04, 0.41 cm). Conflicting evidence for the role of AA (at birth and in
childhood) on changes during development was also found, with higher AA being posi-
tively associated with changes in weight, BMI and Tanner stage, but negatively with
changes in height and fat mass.
Conclusions: We found evidence that being ahead of one’s epigenetic age acceleration is
related to developmental characteristics during childhood and adolescence. This demon-
strates the potential for using AA as a measure of development in future research.
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Introduction
Statistical models that use an individual’s DNA methylation
levels to estimate their age (known as epigenetic clocks)
have been developed.1–5 These methods have proved suc-
cessful, with up to 96% correlation and a mean difference
of 3 years found between estimated and actual age.2 A re-
cent review6 has also highlighted two separate processes
when it comes to age-related changes of DNA methylation
levels: one reflecting overall changes in DNA methylation
across CpG sites over the life course (sometimes referred to
as epigenetic drift7–9), which may be attributed to individual
level environmental factors or stochastic processes. The se-
cond uses specific CpG sites that are affected by age in a
similar fashion across individuals, and hence can be used to
accurately predict age from DNA methylation data.
Differences between chronological age and epigenetic age
are defined as age acceleration (AA) and positive age accel-
eration (i.e. having a higher epigenetic age than chronolo-
gical age) has been shown to be associated with obesity,10
lower physical and cognitive function,11 Alzheimer’s dis-
ease,12 HIV,13 menopause14 and all-cause mortality.15–17
Since DNA methylation can be influenced by environmental
factors,18 and in turn influence phenotypes, it is of interest
to study both the determinants and consequences of AA.
However, there is an absence of literature on the associ-
ations of AA with physical development in early life. The
Avon Longitudinal Study of Parents and Children
(ALSPAC)19,20 is a large UK birth cohort, which has fol-
lowed roughly 14 000 children from birth, collecting many
thousands of variables over time. DNA methylation data
were obtained for 1018 of these children from umbilical
cord blood (at birth) and venous blood at ages 7 and 15 or
17 years as part of the Accessible Resource for Integrated
Epigenomic Studies (ARIES) project.21
Here we use the epigenetic clock method by Horvath,
for the following reasons: first, it is more accurate than
other methods when it comes to young subjects22,23;
second, it applies to virtually all tissues and cell types,
which suggests that it might play a role in organismal de-
velopment and ageing. Using the Horvath age estimation
method, we have calculated the epigenetic age for all of the
children at each time point, and the resulting AA. In this
paper, we investigate the consequences of AA, by looking
at standard measures of development, which have been re-
peatedly measured throughout childhood and adolescence:
height, weight, body mass index (BMI), bone mineral dens-
ity (BMD), bone mass, lean mass and fat mass.
Methods
Study population
This study used DNA methylation data generated under
the auspices of the ALSPAC.19,20 ALSPAC recruited 14
541 pregnant women with expected delivery dates between
April 1991 and December 1992. Of these initial pregnan-
cies, there were 14 062 live births and 13 988 children
who were alive at 1 year of age. The study website contains
details of all the data that are available through a fully
searchable data dictionary (http://www.bris.ac.uk/alspac/
researchers/data-access/data-dictionary).
As part of the ARIES21 project (http://www.ariesepige
nomics.org.uk), a sub-sample of 1018 ALSPAC mother–
child pairs had DNA methylation measured using
the Infinium HumanMethylation450 BeadChip (Illumina,
Inc.)24 Here, we use DNA methylation data generated
from cord blood and venous blood samples at age 7 and
again at age 15 or 17 years, leading to three measurements
of DNA methylation per child. All DNA methylation wet-
lab and preprocessing analyses were performed at the
University of Bristol as part of the ARIES project and has
been described in detail previously.21,22
Key Messages
• Children with a positive epigenetic age are taller and have higher fat mass throughout childhood and adolescence on
average.
• Epigenetic age acceleration is associated with longitudinal changes in weight, BMI, height and fat mass during child-
hood and adolescence.
• We find some evidence that higher epigenetic age is positively associated with longitudinal Tanner stage of develop-
ment in adolescents.
• We find no association between epigenetic age and age at puberty, estimated as the age at peak height velocity.
550 International Journal of Epidemiology, 2017, Vol. 46, No. 2
Downloaded from https://academic.oup.com/ije/article-abstract/46/2/549/2907775
by guest
on 06 February 2018
Epigenetic age
Using the online epigenetic clock calculator (http://labs.gen
etics.ucla.edu/horvath/dnamage/), we obtained epigenetic
age for each child at each time point in ARIES. Along with
epigenetic age, the online calculator estimates cell-type
proportions and calculates raw AA differences (estimated
chronological age) and AA residuals (the residuals from a
linear regression of epigenetic age on chronological age,
which we call age acceleration and denote as ‘AA’). These
AAs are uncorrelated with chronological age and contain
information about the epigenetic age profiles of each sam-
ple, i.e. a positive residual corresponds to an individual
whose epigenetic age is ahead of their chronological age
and vice versa. The calculator provides estimates of epigen-
etic age, AA and AA adjusted for imputed blood cell types.
In our analysis, we use those AA residuals which have been
adjusted for estimated cell-type ratios.
Developmental variables
We obtained longitudinal data on repeatedly measured
physical characteristics in ALSPAC to investigate the rela-
tionship between AA and development. These characteris-
tics were height (cm), weight (kg), BMI (kg/m2), BMD (g/
cm2), bone mass (g), fat mass (g) and lean mass (g). Height,
weight and BMI were measured from birth to age 18 years,
with up to 19 measurements per child, including nine after
age 7 years; BMD, bone mass, fat mass and lean mass were
assessed by dual energy X-ray absorptiometry (DXA) scans
twice, at ages 9 and 18 years. Age at puberty was estimated
by age at peak height velocity (PHV)25 calculated using the
SITAR model.26 We included estimated age at puberty in
all longitudinal models of development and also investi-
gated whether it was related to AA. Tanner (25) staging
was repeatedly measured at mean ages 8.2, 9.7, 10.8, 11.8,
13.2 and 14.7 years. At each of these six ages, participants
were asked to mark their development in relation to draw-
ings of breasts (female), testes (male) and pubic hair (both
male and female) development which were on a graphical
scale from 1 (no development) to 5 (adult development).
Statistical analysis
A single multilevel model was used to investigate the asso-
ciation between chronological and epigenetic ages. Using
the multilevel model, we can include the measures of epi-
genetic age (as a repeated outcome) and calculate an intra-
class correlation coefficient (ICC)—a number between 0
and 1 that suggests the proportion of variation (here in epi-
genetic age) which is explained by between-individual dif-
ferences. The association between AA and developmental
timing was assessed using Pearson correlation between AA
(at birth, age 7 and age 17 years) and SITAR-estimated age
at PHV. Multilevel models of the four ordinal Tanner stage
variables, corrected for age at Tanner measurement, were
used to assess the association of AA at birth and age 7
years on developmental timing. We also combined the
pubic hair Tanner stage variables for boys and girls, and
the breast/testes Tanner stage variables across boys and
girls, in order to increase the power to detect an associ-
ation with AA. Each model was adjusted for longitudinal
cell composition estimated using the Houseman method.27
Body composition data were modelled using multilevel
models,28,29 with AA (at birth and 7 years) included as a
fixed effect along with an interaction of AA (at birth and
age 7 years) with age to determine the effect of AA on
changes in developmental characteristics. AA at age 17
years was not considered as an exposure, since it was re-
corded at the end the follow-up period, with few measures
of the key traits occurring after it. In each multilevel
model, we included sex, birth weight, gestational age, par-
ity, delivery method, maternal age, maternal smoking, ma-
ternal alcohol consumption and maternal education level
attained to adjust for potential confounding. Longitudinal
cell counts (estimated using the Houseman method27) were
also included, to adjust for the effect of changes in blood
cell composition over the life course. To correct for tem-
porality issues, only measures of development taken after
AA were included in the multilevel models, e.g. AA at age
7 could only affect height measures after age 7 years.
Weight was log-transformed to correct for non-constant
variance over age (variance of weight increases over the life
course). Cubic spline terms were used to account for the
non-linear changes in height, log-weight and BMI. The
placement of knots was based on previous research.30–32
For example, the multilevel model for height was:
heightij ¼ b0i þ b1iageij þ b2AA0 þ b3AA7 þ b4AA0  ageij
þb5AA7  ageij þ fiðageijÞ þ b6sex þ b7parity þ b8birthweight
þb9gestationalage þ b10caesarean þ b11maternalage þ b12maternalsmoking
þb13maternalalcohol þ b14maternaleducaiton þ b15CD8tCellsProp
þb16CD4tCellsProp þ b17NaturalKillerCellsProp þ b18BcellsProp
þb19MonocytesProp þ b20GranulocytesProp;
where heightij is the jth height measurement from the ith indi-
vidual for i¼ 1, . . . , n individuals and j¼1, . . . , ni measures.
b0i and b1i represent the ith individual’s random intercept and
slope; fi is a cubic spline which explains the height trajectory
of individual i; b2 and b3 explain the association of age accel-
eration [at birth (AA0) and age 7 years (AA7), respectively]
and average development; b4 and b5 explain the association
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of AA [at birth (AA0) and age 7 years (AA7), respectively] on
changes in development; b6 to b14 describe associations be-
tween development and confounder variables; and b15 to b20
control for estimated cell composition.27
Sensitivity analyses
We carry out two sensitivity analyses, modelling longitu-
dinal physical development as above (A) with adjustment
for age at puberty estimated using SITAR26 and (B) with-
out adjusting for cell-type composition estimated using the
Houseman method.27
Results
A summary of the cohort under investigation is given in
Table 1. Epigenetic age at birth was 0.26 years on average;
chronological age was lower than epigenetic age at the
childhood time point (mean chronological 7.49, epigenetic
8.25) but similar at the adolescent time point (mean
chronological 17.14, epigenetic 17.20). We find low
Pearson correlation coefficients between chronological age
and estimated age (r ¼ 0.058 and 0.245 at childhood and
adolescence, respectively); this reflects the low standard de-
viations in chronological age (SD ¼ 0.15 in childhood, SD
¼ 1.01 years in adolescence). High correlations (such as
the r ¼ 0.96 observed in the studies used to develop the
measure of epigenetic age) were observed in data sets
comprising a wide range of chronological ages.2
Correlations between estimated age and actual age are
similar to the original Horvath paper when including data
from across multiple time points; taking one random meas-
ure from each person, the correlation between epigenetic
and actual age was 0.85 (Figure 1). Using a multilevel
model including all measures of epigenetic and actual age,
the coefficient of age was 0.985 [95% confidence interval
(CI) 0.97, 1.00]. This suggests that, for each year of life,
epigenetic age increases by 0.985 years on average. From
this model, the intra-class correlation coefficient for epi-
genetic age was 0.12, which suggests that 12% of the vari-
ation in epigenetic age is between individuals.
AA at birth
AA was not associated with average length at birth
(0.16 cm per year of AA, 95% CI –0.08, 0.39 cm;
Table 1. Characteristics of the ARIES sample
Variable Time point Mean SD Min. Max. N (%)
Age (years) years 7.49 0.15 7.10 9.08
17 years 17.14 1.01 14.69 19.33
DNA methylation age (years) Birth 0.26 0.63 –0.59 16.68
7 years 8.25 2.42 2.50 24.80
17 years 17.20 4.34 3.77 31.65
Height (cm) 7 years 126.24 5.29 109.20 141.60
17 years 171.93 9.11 152.20 197.50
Weight (kg) 7 years 26.22 4.73 17.60 51.40
17 years 66.99 14.92 44.20 147.40
BMI (kg/m2) 7 years 16.37 2.22 12.65 29.15
17 years 22.61 4.47 16.26 50.06
BMD (g/cm2) 17 years 1.19 0.10 0.95 1.56
Bone mass (g) 17 years 2814 547 1683 4666
Fat mass (g) 17 years 18 005 11 478 3485 82 194
Lean mass (g) 17 years 46 623 10 106 27 535 76 425
Birth weight (g) 3418 547 645.00 5640
Gestational age at delivery (weeks) 39.46 1.86 25.00 47.00
Parity (# previous pregnancies) 0.7 0.8 0 5
Maternal age at pregnancy (years) 29.2 4.4 17 42
Sex Male 445 (49)
Female 469 (51)
Delivery method Caesarean 83 (9)
Natural 795 (91)
Maternal smoking in pregnancy Never 545 (61)
Quit 248 (28)
Smoker 101 (11)
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P¼ 0.19) or height growth (0.017 cm/year per year of AA,
95% CI –0.067, 0.10 cm/year; P¼ 0.69). There was evi-
dence that children with higher AA at birth had faster
growth in weight (0.25%/year faster growth per year of
AA, 95% CI 0.034, 0.459%/year; P¼ 0.023) and BMI
(0.035 kg/m2/year faster growth per year of AA, 95% CI –
0.0037, 0.066 kg/m2/year; P¼ 0.030) during childhood
and adolescence. There was little evidence for an associ-
ation between AA at birth and either average BMD
(0.003 g/cm3 per year of AA, 95% CI –0.006, 0.012 g/cm3;
P¼ 0.478) or bone mass (19.71g per year of AA, 95% CI –
30.8, 70.2 g; P¼ 0.45). A 1-year higher AA at birth was
associated with 1321-g higher fat mass on average across
childhood (95% CI 386, 2256 g; P¼ 0.006), but this dif-
ference narrowed over time, with higher AA children hav-
ing a slower growth of fat mass during childhood and
adolescence (112.5 g/year slower growth, 95% CI 31,
194 g/year slower; P¼ 0.007). AA at birth was not associ-
ated with average lean mass (–74.5g per year of AA, 95%
CI –1502, 1353 g; P¼ 0.918).
AA in childhood
Higher AA at age 7 was associated with increased height
(Table 2). Children with a 1-year higher AA at 7 were
0.23 cm taller on average (95% CI 0.04, 0.41 cm;
P¼ 0.018) between 7 and 17 years of age. AA at age 7 was
also associated with changes in height, with a 1-year
positive AA being associated with slower growth of height
(–0.031 cm/year, 95% CI –0.005, –0.057 cm/year;
P¼ 0.021) from 7 to 17 years. There was no evidence of
an association between AA at age 7 and either average
weight (–0.11% per year of AA, 95% CI –0.69, 0.48%;
P¼ 0.72) or BMI (–0.04 kg/m2 per year of AA, 95% CI –
0.11, 0.03 kg/m2; P¼ 0.28). We did not identify any
associations between AA at age 7 and either average BMD
(–0.001 g/cm3 per year of AA, 95% CI –0.0036, 0.0015 g/
cm3; P¼ 0.418), bone mass (–7.16 g per year of AA, 95%
CI –21.8 g, 7.5 g; P¼ 0.34), fat mass (67.2 g per year of
AA, 95% CI –205, 339 g; P¼ 0.63) and lean mass (–206g
per year of AA, 95% CI –605, 192 g; P¼ 0.24).
Role of age at puberty
AA at birth (Pearson r¼ 0.006, P¼ 0.85), 7 years
(r¼ 0.014, P¼0.67) and 17 years (r¼ 0.014, P¼ 0.66)
were not associated with age at PHV estimated by the
SITAR model. The odds ratios from multilevel models of
ordinal Tanner stages of development are presented in
Table 3. Those boys with a positive epigenetic age at birth
had higher odds of increasing Tanner stage of testes devel-
opment (OR 1.10, 95% CI 1.01, 1.20; P¼ 0.03). Further,
combining across both sexes, there was some evidence that
those children with positive epigenetic age at birth had
higher odds of increasing pubic hair development in ado-
lescence (OR 1.05, 95% CI 1.00, 1.11; P¼0.06). There
was no evidence that AA at age 7 was associated with any
longitudinal Tanner measure of development.
Figure 1. Epigenetic age against actual age for a random sample of 1000 ARIES offspring taken from across the three time points.
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Sensitivity analysis
In Table 4, we provide the results of models that are ad-
justed for age at puberty, for comparison with Table 2.
Whereas there is a general pattern of attenuation of the as-
sociations of AA with physical development after adjust-
ment for age at puberty, there are no changes to the overall
patterns of association described in the previous sections.
Table 5 displays results unadjusted for longitudinal cell
composition, as estimated by the Houseman method.27
Here, AA at age 7 appears to be associated with changes in
both bone mass and lean mass. Associations between AA
at 7 and height are similar with and without adjustment, as
are all associations of AA at birth.
Table 3. Results from multilevel ordinal models of Tanner stage variables against age acceleration at birth and age 7 years, con-
trolling for age at measurement of Tanner stage
Outcome Exposure Odds ratio
(per year of AA)
95% CI P-value n
Tanner girls genitals AA at 0 1.11 0.87, 1.42 0.39 459
AA at 7 0.99 0.73, 1.34 0.94 458
Tanner girls pubic hair AA at 0 1.11 0.65, 1.88 0.70 410
AA at 7 1.11 0.60, 2.07 0.74 415
Tanner boys genitals AA at 0 1.10 1.01, 1.20 0.03 477
AA at 7 1.04 0.94, 1.15 0.44 475
Tanner boys pubic hair AA at 0 1.00 0.92, 1.07 0.90 448
AA at 7 0.96 0.88, 1.05 0.37 453
Tanner genitals AA at 0 1.00 0.92, 1.07 0.90 448
AA at 7 0.96 0.88, 1.05 0.37 453
Tanner pubic hair AA at 0 1.05 1.00, 1.11 0.06 925
AA at 7 0.99 0.93, 1.06 0.79 928
Table 2. Age acceleration and physical developmenta
Outcomeb Exposure Mean
difference in
outcome per
1-year greater AA
95% CI P-value Mean
difference in
change in outcome
per year per 1-year
greater AA
95% CI P-value
Height (cm) AA at 0 0.16 –0.08, 0.39 0.184 0.012 –0.071, 0.094 0.783
AA at 7 0.23 0.04, 0.41 0.018 –0.031 –0.057, –0.005 0.021
Weight (%)c AA at 0 –1.16 –2.86, 0.57 0.189 0.246 0.034, 0.459 0.023
AA at 7 –0.11 –0.69, 0.48 0.719 –0.001 –0.072, 0.071 0.981
BMI (kg/m2) AA at 0 –0.07 –0.18, 0.04 0.227 0.035 0.003, 0.066 0.030
AA at 7 –0.04 –0.11, 0.03 0.282 0.004 –0.01, 0.01 0.423
BMD (g/cm2) AA at 0 0.0032 –0.0056, 0.0119 0.478 –0.0002 –0.0010, 0.0006 0.600
AA at 7 –0.0010 –0.0036, 0.0015 0.418 0.0001 –0.0001, 0.0003 0.298
Bone mass (g) AA at 0 19.71 –30.83, 70.24 0.445 –0.66 –4.98, 3.66 0.765
AA at 7 –7.16 –21.84, 7.51 0.339 1.07 –0.16, 2.31 0.089
Fat mass (g) AA at 0 1320.8 385.85, 2255.7 0.006 –112.58 –194.39, –30.77 0.007
AA at 7 67.26 –204.73, 339.24 0.628 –3.92 –27.30, 19.46 0.742
Lean mass (g) AA at 0 –74.51 –1501.6, 1352.5 0.918 20.72 –80.98, 122.43 0.690
AA at 7 –206.22 –605.36, 192.92 0.311 20.45 –7.77, 48.67 0.155
aAll models adjusted for estimated cell counts, sex, birth weight, gestational age, parity, delivery method, maternal age, maternal smoking, maternal alcohol
consumption and maternal education level attained.
bAll outcome measurements come either concurrently or after the age at which AA is estimated.
cWeight was log-transformed such that back-transformed coefficients represent % change in weight.
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Discussion
Positive epigenetic AA in early life appears to be associated
with several developmental variables and changes in these
variables during childhood. We have identified positive as-
sociations between AA and average height, average fat
mass, and increased weight and BMI gain. Conversely,
Table 4. Age acceleration and physical development with adjustment for age at pubertya
Outcomeb Exposure Mean
difference in
outcome per
1-year greater AA
95% CI P-value Difference in
average change in
outcome per 1-year
positive AA
95% CI P-value
Height (cm) AA at 0 0.17 –0.07, 0.40 0.167 0.009 –0.074, 0.092 0.828
AA at 7 0.22 0.04, 0.41 0.019 –0.031 –0.058, –0.005 0.022
Weight (%)c AA at 0 –0.95 –2.60, 0.72 0.262 0.198 0.001, 0.396 0.049
AA at 7 –0.13 –0.69, 0.44 0.653 0.002 –0.064, 0.069 0.949
BMI (kg/m2) AA at 0 –0.06 –0.18, 0.05 0.271 0.032 0.001, 0.063 0.042
AA at 7 –0.04 –0.11, 0.03 0.245 0.005 –0.01, 0.01 0.356
BMD (g/cm2) AA at 0 0.0026 –0.0063, 0.0115 0.565 –0.0002 –0.0010, 0.0006 0.617
AA at 7 –0.0012 –0.0037, 0.0014 0.379 0.0001 –0.0001, 0.0003 0.268
Bone mass (g) AA at 0 17.21 –34.08, 68.50 0.511 –0.68 –4.99, 3.63 0.756
AA at 7 –7.93 –22.80, 6.93 0.295 1.03 –0.20, 2.27 0.101
Fat mass (g) AA at 0 1253.7 325.44, 2182.0 0.008 –111.41 –191.95, –30.88 0.007
AA at 7 40.43 –229.68, 310.54 0.769 –3.79 –26.88, 19.30 0.748
Lean mass (g) AA at 0 –93.80 –1513.8, 1326.2 0.897 19.67 –81.48, 120.83 0.703
AA at 7 –239.08 –636.16, 157.99 0.238 21.93 –6.13, 49.98 0.126
aAll models adjusted for age at puberty, estimated cell counts, sex, birth weight, gestational age, parity, delivery method, maternal age, maternal smoking, ma-
ternal alcohol consumption and maternal education level attained.
bAll outcome measurements come either concurrently or after the age at which AA is estimated.
cWeight was log-transformed such that back-transformed coefficients represent % change in weight.
Table 5. Age acceleration and physical development without adjusting for cell type proportionsa
Outcomeb Exposure Mean
difference in
outcome per 1-year
greater AA
95% CI P-value Mean difference
in change in outcome
per year per 1-year
greater AA
95% CI P-value
Height (cm) AA at 0 0.17 –0.06, 0.40 0.142 0.011 –0.072, 0.093 0.802
AA at 7 0.21 0.03, 0.40 0.025 –0.033 –0.059, –0.007 0.014
Weight (%)c AA at 0 –0.99 –2.68, 0.74 0.260 0.233 0.018, 0.448 0.034
AA at 7 –0.09 –0.67, 0.49 0.751 –0.002 –0.074, 0.071 0.966
BMI (kg/m2) AA at 0 –0.08 –0.19, 0.03 0.151 0.035 0.004, 0.066 0.028
AA at 7 –0.04 –0.10, 0.03 0.304 0.004 –0.01, 0.01 0.413
BMD (g/cm2) AA at 0 0.0026 –0.0061, 0.0114 0.556 –0.0002 –0.0010, 0.0006 0.596
AA at 7 –0.0015 –0.0040, 0.0010 0.235 0.0001 –0.0001, 0.0004 0.218
Bone mass (g) AA at 0 14.79 –36.80, 66.38 0.574 –0.58 –4.97, 3.80 0.794
AA at 7 –11.99 –26.50, 2.52 0.105 1.29 0.05, 2.54 0.042
Fat mass (g) AA at 0 1289.8 355.91, 2223.7 0.007 –108.21 –190.09, –26.34 0.010
AA at 7 81.73 –181.36, 344.83 0.543 –5.03 –28.25, 18.18 0.671
Lean mass (g) AA at 0 –140.32 –1605.1, 1324.4 0.851 21.15 –82.88, 125.18 0.690
AA at 7 –306.20 –708.80, 96.41 0.136 25.33 –3.32, 53.97 0.083
aAll models adjusted for sex, birth weight, gestational age, parity, delivery method, maternal age, maternal smoking, maternal alcohol consumption and mater-
nal education level attained.
bAll outcome measurements come either concurrently or after the age at which AA is estimated.
cWeight was log-transformed such that back-transformed coefficients represent % change in weight.
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there were negative associations between AA and changes
in height and fat mass. A systematic difference between
epigenetic and actual age at the ARIES childhood time
point was found (mean actual 7.49 years, mean epigenetic
8.25 years). There may be population differences between
the ARIES population and the cohorts of children used to
develop the Horvath age estimation method. For example,
the Alisch et al. data set33 has a higher proportion with
non-European ancestry (>15%) and uses the Illumina 27k
rather than 450k array to estimate epigenetic age. The sys-
tematic difference at childhood could further be influenced
by the spread of the estimated epigenetic ages for the child-
hood time point (standard deviation 2.4 years, range 2.5–
25 years) when compared with the spread of actual age at
childhood (standard deviation 0.15 years, range 7.1–9.1
years).
The findings reported here are independent of sex (sex
differences in AA have been previously reported22), with
all analyses controlled for sex. Those children with higher
AA at age 7 are taller on average with lower lean and bone
mass. This suggests that there may be an identifiable devel-
opmental type, with higher AA in early life. Studies of AA
in adults have identified a positive association between AA
and obesity10 and all-cause mortality.15 Given that BMI
and general adiposity are associated with an increased risk
of mortality,34,35 this suggests an epigenetic age lower than
one’s actual age (i.e. negative AA) is desirable. We have
found some evidence to suggest that growth of BMI is
faster in children whose DNA methylation levels at birth
lead to a positive AA. This is congruent with several previ-
ous findings10,22 and suggests the link between AA and
BMI manifests from birth. However, it is not yet clear
whether positive AA is harmful during childhood. Indeed,
it could be taken from our results that a positive AA sug-
gests above-average development (which is not always a
health positive, e.g. BMI). For example, we have also iden-
tified positive associations between AA and height and fat
mass.
Whereas our study found at best a suggestive relation-
ship between AA at birth and the role of sex hormones
(Tanner stage), another study in adults found that the loss
of sex hormones (resulting from menopause) was associ-
ated with increased epigenetic AA in blood.14 However,
we did not identify any association between AA and age at
puberty (estimated by age at PHV). One might expect that
age at puberty (an obvious marker of developmental age)
would be associated with epigenetic age but its inclusion in
the modelling of development failed to influence the effect
of AA. Further, a recent study of children who suffer from
a severe developmental disorder found no evidence for a
difference in epigenetic and chronological age.23 These null
findings temper our conclusions on the relationship
between AA and physical development. On the other hand,
measurement error and tissue specificity may play a role.
We used age at PHV (i.e. the age at which adolescents
grow fastest) estimated by the SITAR model26 as a marker
for age at puberty. Obtaining an accurate measure of age
at puberty is difficult, and our null finding may be to do
with poor estimates of age at puberty. Another possibility
is that blood cells are not the optimal tissue for relating
epigenetic age and physical development.
Future longitudinal studies of AA may be able to pro-
vide evidence as to the changing role of epigenetic age
across the life course. Causal inference methods, such as
Mendelian randomization,36 should be implemented to in-
vestigate the influence of epigenetic age and AA37 on devel-
opment, perhaps using genetic variants close to the 353
CpG sites (these are described in our Supplementary data,
available at IJE online) which are used to estimate epigen-
etic age. Since Mendelian randomization will require a
large sample size to be adequately powered, collaboration
between cohort studies with epigenetic and longitudinal
data will be key to this endeavour.
A novel application of the epigenetic clock in physical
development should involve the comparison of epigenetic
age (and AA) between tissue types on the same individuals.
Comparisons of epigenetic age of bone, blood and adipose
tissue, for instance, could lead to novel insights into well-
known associates of development and how they interact
with changes across the life course. Another potential
avenue is to use AA as an aggregate measure of develop-
ment. Whereas our analysis has identified several associ-
ations, larger studies could identify stronger (and possibly
causal) links between AA and development. Using AA as a
marker for development would simplify analyses where
difficulty lies in choosing which aspects of development to
adjust for.
We have not been able to replicate our longitudinal ana-
lysis findings in an independent cohort due to the unique
nature of our data set. Since measured cell-type propor-
tions were not available in ARIES, we have adjusted
for estimated cell-type proportions from the online calcula-
tor (http://labs.genetics.ucla.edu/horvath/dnamage/), which
uses the Houseman method.27 This raises the possibility
that differences observed can be explained by longitudinal
(possibly developmental) changes in white blood cell pro-
files not captured by these estimates. Whereas adjusting for
cell type is good practice, care should be taken when ad-
justing for cell composition in early life, since the
Houseman method has not been validated in cord blood
samples or in very young children and it may lead to biased
results. In this manuscript, we have shown the results both
adjusted and unadjusted for Houseman estimated cell
counts. We observed that the association between
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epigenetic age and both bone and lean mass appears to be
explained by changing cell-type composition across child-
hood and adolescence. However, this may be due to a bias
introduced using the Houseman method on cord blood
samples. Recently, reference data sets for cell-type correc-
tion in cord blood have been released.38,39 Unfortunately,
using these in longitudinal modelling through childhood
and adolescence is difficult, since these methods do not es-
timate the same cell types as those in venous blood drawn
from the peripheral circulation.
Our main findings were obtained across seven multi-
level models, each with two parameters of interest, and
should thus be interpreted in light of this multiple testing
burden. The association of AA with changes in height
could be explained by regression to the mean. For instance,
we find positive AA is associated with being taller on
average at age 7, but also that positive AA is associated
with slower growth from 7 to 17 such that, on average,
children will end up with similar heights at age 17 regard-
less of AA.
Epigenetic AA in early life is associated with several de-
velopmental characteristics throughout childhood and ado-
lescence, but with associations not all in the same direction,
and no observed association with age at puberty. The con-
sideration of epigenetic age as an index of developmental
stage is a novel concept that adds to the growing literature
around AA and its use as a measure of development aging.
Further longitudinal and causal analyses are needed to in-
vestigate the influences and consequences of AA.
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